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Abstract
Objective—Liver disease is a frequent cause of morbidity and mortality in HIV infection. We 
examined the relationship of cocaine use, liver disease progression and mortality in an HIV-
infected cohort.
Methods—Consent was obtained from 487 HIV+ participants, a subset of the Miami Adult 
Studies on HIV (MASH) cohort. Participants were eligible if they were followed for at least two 
years, completed questionnaires on demographics and illicit drug use and had complete metabolic 
panels, CD4 cell counts and HIV-viral loads. FIB-4 was calculated and cut-off points were used 
for staging liver fibrosis. Death certificates were obtained.
Results—Participants were 65% men, 69% Black and 81% were on ART at recruitment. Cocaine 
was used by 32% of participants and 29% were HIV/HCV co-infected. Mean age was 46.9 ± 7.7 
years, mean CD4 cell count was 501.9 ± 346.7 cells/μL and mean viral load was 2.75 ± 1.3 log10 
copies/mL at baseline. During the follow-up, 27 patients died, with a mortality rate of 28.2/1000 
person-year. Cocaine was used by 48% of those who died (specific mortality rate was 13/1000 
person-year). Those who died were more likely to use cocaine (HR=3.8, P=0.006) and have more 
advanced liver fibrosis (HR=1.34, P<0.0001), adjusting for age, gender, CD4 cell count and HIV-
viral load at baseline and over time. Among the HIV mono-infected participants, cocaine users 
were 5 times more likely to die (OR=5.09, P=0.006) than participants who did not use cocaine.
Conclusion—Cocaine use and liver fibrosis are strong and independent predictors of mortality in 
HIV infected and HIV/HCV co-infected adults. Effective interventions to reduce cocaine use 
among people living with HIV (PHLW) are needed.
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Introduction
As antiretroviral therapy (ART) increases the lifespan of people living with HIV (PLWH), 
the risk for liver cirrhosis and liver carcinoma increases [1]. Liver disease is one of the 
predominant causes of non-AIDS related death in HIV-infected patients [2–4] due to the 
HIV virus itself [5], high prevalence of co-infection with the hepatitis C virus (HCV) [6, 7] 
and substance abuse [6, 8]. HIV infection is implicated in the development of hepatic 
fibrosis even in the absence of hepatitis B and C, alcohol use and ART [5]. Survival rates of 
PLWH, who do not use illicit drugs, are significantly higher compared to those who use 
drugs even in settings with access to ART [4]. Moreover, HIV infected drug users are at a 
high risk for HCV co-infection [9] which is associated with increased rates of liver fibrosis, 
higher rates of cirrhosis, and more rapid progression to end-stage liver disease [10–12].
Despite promising new interventions to address HCV co-infection [13], cocaine use [8, 14] 
continues to be of interest due to its fibrogenic potential [15]. In addition, HIV infected 
illicit drug users have lower access to HIV and HCV treatments [16–19] and are at greater 
risk for treatment failure due to lower adherence to treatment [20]. In HIV/HCV co-infected 
patients, therapeutic cure of HCV infection may not reduce or reverse hepatic fibrosis and its 
complications [21, 22]. Patients may not achieve sustained virological response (SVR), may 
develop occult Hepatitis C [23], which will affect immune recovery [24, 25], may 
decompensate due to drug and alcohol abuse [26], or develop hepatic malignancy, even after 
HCV is controlled [27].
Liver injury, regardless of the underlying etiology, is associated with hepatic fibrosis, a 
wound healing process characterized by excessive deposition of the extracellular matrix and 
scar formation [28], leading to increased morbidity and mortality [29]. HIV infection is 
directly implicated in the development of hepatic fibrosis even in the absence of other strong 
risk factors such as hepatitis B and C infection, alcohol abuse and ART use [5].
Cocaine activates latent HIV-1 infection, increases HIV viral load [8, 30, 31], depresses 
immune response, [14, 30, 32–35] and accelerates HIV disease progression [8, 30, 32]. 
Cocaine also activates cytokines associated with progression of liver fibrosis as observed in 
in vitro studies [8, 14]. In this study, we examined the relationship of cocaine use, HIV/HCV 
co-infection, and progression of liver fibrosis and mortality in an HIV-infected cohort. The 
objectives were to determine (1) the association of cocaine use and degree of liver fibrosis at 
baseline and over time in a clinically relevant progression of liver disease; and (2) whether 
cocaine use and stage of liver fibrosis were associated with mortality during a follow-up. 
The findings from this investigation suggest that cocaine use facilitates progression of liver 
fibrosis and mortality in HIV mono-infected and HIV/HCV co-infected adults. Our 
longitudinal findings are important, because they identify factors and clinical correlates of 
morbidity and mortality in HIV infected cocaine users, which have the potential to guide the 
development of effective interventions [16, 36–38].
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Since cocaine is the major drug of abuse in our Miami Adult Studies on HIV (MASH) 
cohort, and drug rehabilitation has largely been unsuccessful in attaining lasting cocaine 
abstinence [39–42], the results from this study can contribute to a better understanding of the 
clinical consequences of cocaine use to accelerate the development of targeted programs 
which might delay mortality, [8, 43, 44] a public health priority [16].
Methods
Study design
This was an observational longitudinal study of 487 HIV+ participants followed for at least 
two years to assess cocaine use, changes in liver fibrosis measured by the liver fibrosis index 
(FIB-4) and mortality. Participants were a subset of the more than 800 participants from the 
MASH cohort that has been followed for the last ten years. This study was approved by the 
Florida International University Institutional Review Board. Appropriate written informed 
consent was obtained from all participants and clinical research was conducted in 
accordance with guidelines for human experimentation as specified by the US Department 
of Health and Human Services and/or authors’ institutions.
To qualify for this investigation, participants needed to be 18–59 years old, have HIV sero-
positivity confirmed by medical documentation, and drug use determined by a drug-
frequency questionnaire and confirmed by urine toxicology. Participants with uncontrolled 
diabetes, cirrhosis, hepatitis B infection and kidney failure were excluded. History of HIV 
infection and hepatitis A, B or C was obtained from the medical record review.
After obtaining informed consent and screening for eligibility, participants’ demographic, 
medical and drug-related information was obtained from the MASH cohort study charts. 
Patients were followed for a median of 4.3 years IQR (1–1.08 years). Data for parameters of 
liver fibrosis were obtained from the participants’ at baseline and 24 month visits. Mortality 
follow-up was conducted from the study baseline for 6 years, and time of diagnosis was 
obtained from the medical charts. During the MASH visits, a physical examination was 
completed and anthropometrics were measured. After overnight fasting, blood samples were 
obtained for complete blood cell count and blood chemistry that included the liver enzymes 
alanine aminotransferase (ALT) and aspartate aminotransferase (AST), and platelet counts 
(PLT) to estimate the fibrosis index (FIB-4). CD4 cell count and HIV viral load were 
obtained from the participants’ medical records.
Assesments
Body mass index
Weight and height were obtained in participants wearing light clothing and no shoes 
utilizing a standard scale calibrated prior to each measurement. Height was measured with 
the participant’s heels touching the base of the vertical board of the stadiometer. The 
moveable headboard was brought to the most superior point on the head with sufficient 
pressure to compress the hair. Body mass index (BMI) was calculated using the standard 
formula that divides weight in kilograms by the square of height in meters (kg/m2).
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Medical history and review of medical records
Medical history included medical visits, currently prescribed medications, past and current 
use of ART and adherence in the previous 6 months; a review of records was used to verify 
prescriptions, determine changes in ART, and confirm diagnosis.
Staging liver disease
A non-invasive measure to estimate liver fibrosis, the fibrosis index (FIB-4), was calculated 
using routine laboratory tests as follows: [age (years) × AST (U/L)]/[PLT (109 cells/L) × 
ALT1/2 (U/L)] [45]. Liver fibrosis stages F0–F1 correspond to FIB-4<1.45; F2–F3 to ≥ 1.45 
but ≤ 3.25; and F4 to FIB-4 >3.25 [46]. At a cut-off point of <1.45 (equivalent to Metavir 
stage F0–F1), the negative predictive value to exclude advanced fibrosis (Metavir stage F4) 
was 90% with a sensitivity of 70%. A cut-off of >3.25 (equivalent to Metavir stage F-4) had 
a positive predictive value of 65% and a specificity of 97% to predict advanced disease [46].
Substance abuse questionnaires
Drug, alcohol and tobacco use questionnaires were administered by trained and certified 
interviewers. The drug use questionnaires were validated against blood metabolites and 
urine screening [30] and described previously [31, 47]. Cocaine users were defined as 
participants who admitted to cocaine use by self-report and/or had at least one positive urine 
toxicology (N=156). Cocaine use frequency was captured through validated questionnaires 
and scored as: 0=never, 1=once a month, 2=once a week, 3=3–4 times a week, 4=daily and 
5=more than daily. Frequency of use was obtained from participants who admitted using 
during their assessment visits (N=80). Alcohol use was obtained using the validated and 
standardized Alcohol Use Disorders Identification Test (AUDIT) questionnaire that detects 
frequency of use, hazardous and dependent drinking, and binge drinking [48].
Urine toxicology
Urine was collected under observation at each study visit. The American Biomedica Rapid 
Drugs kits were used to confirm self-report for cannabinoids, cocaine, methadone, 
methamphetamines and opiates.
Death certificates
Death certificates were obtained from the State of Florida Department of Vital Statistics 
through a research agreement to verify time and cause of death and to determine whether the 
death was HIV-related.
Statistical Analysis
To characterize the population, we used descriptive statistics that were expressed as mean ± 
standard deviation (SD) or as percent of population. Significance was defined as P<0.05. 
The Cox proportional hazard model was employed to derive adjusted hazard ratios after 
testing for non-violation of the proportionality assumption in each case. We confirmed this 
by plotting the log-negative-log of the Kaplan-Meier estimates of the survival function 
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versus the log of time using ‘R’ statistical software, version 3.1.1. The resulting curves were 
parallel [49]. The computed hazard was determined by:
h (t)=h0 (t) × exp {b1 × 1+b2 × 2+...+bpxp} where the hazard function is represented by h 
(t) and is determined by a group of covariates (x1, x2 ..., xp) whose effect is measured by the 
size of the individual coefficients (b1, b2, ..., bp) and t is the survival time. All statistical 
analysis were performed using SAS statistical software, version 9.4. Mixed models were 
used to assess the effect of cocaine on liver fibrosis over two years. Participants in both 
groups were in a waiting list for ART at baseline, depending on when they were diagnosed, 
but were referred for treatment during participation. The great majority received treatment 
within one year of starting in the study, as ART became more accessible in Miami-Dade. 
The analyses were adjusted for viral load at baseline and over time, because viral load 
control was a stronger predictor of disease progression and mortality than just receiving 
ART. All the analyses were also adjusted for age, gender, CD4 cell count and HIV-viral load 
at baseline and over time.
Results
Characteristics of the population
There were a total of 487 participants, a subset of the MASH cohort, who were followed for 
the markers of liver disease progression and death. Participants were mostly men (65%), 
African Americans (68%) and receiving ART (81%) at baseline. Thirty-two percent used 
cocaine and 29% were HIV/HCV co-infected. Mean age was 46.9 ± 7.7 years, mean CD4 
cell count was 501.9 ± 346.7 cells/μL and mean viral load was 2.75 ± 1.3 log10 copies/mL at 
baseline (Table 1). During the follow-up, 27 patients died, with a mortality rate of 28.2/1000 
person-year. Thirteen of these participants (48%) reported cocaine use during the study with 
a specific mortality rate of 13/1000 person-year. Participants who used cocaine had 
significantly lower Body Mass Index (BMI), although the mean BMI was still in the 
“overweight” range (26.9 ± 5.4 kg/m2 cocaine users vs. 27.67 ± 5.1 kg/m2 among non-users, 
P=0.026). Fewer cocaine users received ART at baseline (75% vs. 84%, P<0.001) and they 
had higher HIV viral load than the participants who did not use cocaine (2.97 ± 1.4 log10 
copies/mL vs. 2.64 ± 1.3 log10 copies/mL, P=0.001). Significantly fewer Hispanics but more 
African Americans used cocaine (Table 1).
Effect of cocaine use on liver fibrosis in HIV/HCV co-infected and HIV mono-infected PLWH
Table 2 shows the comparison between cocaine users (32%) and non-users among 
HIV/HCV co-infected and HIV mono-infected participants on advancing liver disease 
progression over a period of two years. Both HIV/HCV co-infected and HIV mono-infected 
cocaine users had significantly faster liver fibrosis progression than non-users. Cocaine use 
among those who were HIV/HCV co-infected was associated with 0.44 unit increase in 
FIB-4 (β=0.44, SE=0.22, P=0.049) and among the HIV mono-infected with an increase of 
0.23 units in FIB-4 (β=0.23, SE=0.11, P=0.033), as compared to cocaine non-use over a 
two-year period. Moreover, cocaine users, both HIV mono-infected and HIV/HCV co-
infected had more than twice the risk of advancing liver fibrosis from FIB-4 <1.45 to >3.25, 
equivalent to clinically significant 2-Metavir stages (OR=2.52, 95% CI 1.15, 5.54, P=0.021), 
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compared to cocaine nonusers (not shown). In addition, a higher proportion of HIV/HCV 
co-infected cocaine users progressed the equivalent of 2-Metavir stages in two years, 
compared to HIV/HCV co-infected cocaine non-users (62.5% vs. 30.4%, P<0.0001).
HIV/HCV co-infected and HIV mono-infected participants who used cocaine daily or more 
than daily, had higher FIB-4 compared to moderate cocaine users and non-users over time 
(β=0.6, SE=0.3, P=0.03). In addition, daily or more than daily use of cocaine was a 
significant predictor of FIB-4 >1.45 in the range of moderate or more severe fibrosis over 
time (β=0.2, SE 0.1, P=0.02) among HIV mono-infected participants.
Effect of cocaine and liver fibrosis on mortality
During the 6-year follow-up, 27 patients died, 13 of whom (48%) reported cocaine use 
during the study. The mortality was higher among cocaine users (13/156, 8.33%) compared 
to non-users (14/331, 4.22%, P=0.003). Twelve participants died among those who were 
HIV/HCV co-infected (12/140, 8.6%) and 15 participants among those who were HIV 
mono-infected (15/347, 4.3%). The specific rate of mortality for participants who were 
HIV/HCV co-infected was 12.32/1000 patient-year. Table 3 shows that HIV/HCV co-
infection significantly predicted death (P=0.035) and those who were co-infected were 2.4 
times more likely to die during the study. HIV mono-infected participants who used cocaine 
were 5 times more likely to die (HR=5.1, CI 95%: 1.6, 16.1, P=0.006) controlling for age, 
gender and HIV viral load at baseline (Table 3). In Table 4, in a Multiple Cox Regression 
Model, those who died were more likely to use cocaine (HR=3.8, CI 95%: 1.5, 9.8, 
P=0.006), have higher FIB-4 at baseline (HR=1.34, 95% CI: 1.18, 1.52, P<0.0001), and 
lower CD4 cell count (HR=0.94, 95% CI: 0.88, 0.99, P=0.0194) than those who survived, 
adjusting for age, gender and HIV viral load at baseline and over time. The majority of death 
certificates (19/27, 70.4%) had multiple causes of death, with 17 certificates listing HIV/
AIDS as a major cause of death, followed with 10 with diagnosis of cardio-respiratory arrest 
(Table 5).
Figures 1–4 depict the Kaplan-Meier Curves comparing the survival of cocaine users 
compared with non-users and survival by stage of liver fibrosis. The outcome event is time 
of death confirmed by a death certificate. Two time frames are considered: from the study 
baseline to the event during a 6 year follow-up in Figure 1 and from the time of HIV 
diagnosis obtained from medical charts to death in Figure 2. The Kaplan-Meier curves in 
both figures indicate a significantly shorter survival time for participants who used cocaine 
than those who did not use cocaine (P<0.05). Figures 3 and 4 compare survival by different 
stages of liver fibrosis estimated by FIB-4 for the two years and show that participants who 
had more severe liver disease had significantly higher rates of survival than those who had 
less severe liver disease (P<0.05).
Discussion
Liver disease is a predominant cause of morbidity and mortality in HIV infection [2–4]. This 
study has shown the association between cocaine use and increased likelihood of liver 
disease progression and death in people living with HIV and those co-infected with HIV and 
HCV. Although the mortality rate of this group is relatively high (28.24 per 1000 person-
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year), it is comparable to that of other HIV infected cohorts that include drug users [50, 51]. 
Cocaine users, both HIV/HCV co-infected and HIV mono-infected, had significantly faster 
liver fibrosis progression and higher rates of mortality than participants who did not use 
cocaine. The association between cocaine use and moderate to severe liver fibrosis 
progression among the HIV mono-infected participants was even stronger than in the 
combined cohort of HIV/HCV co-infected and HIV mono-infected participants, and the 
association of cocaine use with mortality was higher (Table 3). Among these MASH cohort 
participants, the mortality rate was higher in the cocaine users compared to cocaine non-
users (8.33% vs. 4.22%, P=0.003, (Table 1), which is in agreement with other studies 
showing increased rate of death among cocaine users. [52].
In previous reports [30, 31], we established the association of cocaine use with HIV disease 
progression [30] and suggested mechanisms [31] for this effect. The findings of the present 
study support this association and show that both cocaine use and CD4 cell counts, a marker 
of disease progression, remain strongly significant as independent predictors of death in the 
multivariate model (Table 3). In this study, cocaine users had significantly higher HIV viral 
load at baseline (2.97 ± 1.4 vs. 2.64 ± 1.3, P<0.001 (Table 1), which has been previously 
shown to affect liver enzyme elevations and more advanced hepatic fibrosis. Thus, our 
observations support earlier findings of other investigators indicating an association between 
increased HIV viral load and liver fibrosis [5], most likely due to an infection of hepatocytes 
by HIV, inducing liver fibrogenesis [53]. In addition, Dillon et al. [54] reported that cocaine 
activated viral replication in human monocyte-derived macrophages and intra-hepatic 
infiltration of HIV-specific CD8 and has been suggested as a mechanism for rapid liver 
fibrosis in HIV/HCV co-infected patients [55], particularly in those who use cocaine. We 
have shown in this current study that HIV-infected cocaine users not only demonstrate 
higher HIV viral load, but also fewer percent of these participants report taking ART. ART 
has been documented to slow liver disease progression, by both biopsies and clinical events, 
including lowering inflammation, lowering risk of hepatic decompensation and death [56]. 
The results of this study support the earlier findings by other investigators showing that 
cocaine use is independently associated with failure to achieve virologic suppression in HIV 
infected patients [57]. On the other hand, our finding that cocaine use was associated with 
lower BMI in this study, may be protective of hepatic fibrogenesis, as liver disease has been 
previously shown to be associated with obesity [58].
The faster liver disease progression and elevated mortality observed among cocaine users 
compared with non-users in this study may be due to cocaine users having higher viral load 
and lower use of ART, but also to direct damage to the liver by cocaine, which may range 
from just elevated hepatic enzymes to hepatic necrosis precipitated by high cocaine doses 
[59]. In animal models, cocaine has been shown to act as a hepatotoxin, with the cytochrome 
P-450 dependent N-oxidative pathway exerting direct cytotoxic effects through oxidative 
damage causing liver injury [60]. The net amount of reactive species seems to determine the 
severity of hepatic lesions [60]; thus, these findings also may explain the associations of 
higher frequency of cocaine use with faster liver disease progression as the frequency of 
cocaine use increased.
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Another unique finding was that faster liver disease progression and higher rate of cocaine-
related mortality occurred in both HIV/HCV co-infected and HIV mono-infected 
participants. While the effect of high frequency of cocaine use was significantly associated 
with the progression of liver disease and mortality in HIV mono-infected participants, HCV 
co-infection was most likely a stronger driver of liver fibrosis among the HIV/HCV co-
infected participants [61].
In this study we used a non-invasive measure of liver fibrosis, the FIB-4 index, which has 
been suggested as an alternative to liver biopsy in PLWH, due to significant limitations such 
as sampling errors, observer variation and the risk for severe complications such as severe 
bleeding [62, 63]. The FIB-4 index has been validated in HIV/HCV co-infected adults [45, 
64]. Recently, FIB-4 was found to be a better predictor of overall death and liver-related 
events than liver biopsy in HIV/HCV co-infected individuals [64]. Liver biopsy is not 
routinely performed in HIV mono-infected individuals without any liver related disease, 
therefore non-invasive measures of liver damage are appropriate for this population and have 
been performed in other studies with HIV mono-infection.
Limitations
This study determined the associations between cocaine use, the progression of liver disease 
and fibrosis, and mortality among HIV/HCV co-infected and HIV mono-infected PLWH. 
While the participants had a long-term follow-up, the study was observational and therefore 
it is not possible to draw causative inferences. Our findings are also limited by the specific 
characteristics of the population: people living with HIV and substance abuse in Miami, 
which may be very different than other populations of PLWH nationally and internationally.
Conclusion
Cocaine use increased the likelihood of progression of liver fibrosis and death in HIV mono-
infected and HIV/HCV co-infected participants. Findings from this study suggest that 
cocaine use in PLWH has deleterious effects on viral control, progression of liver disease 
and survival and that the detrimental impact of cocaine use remains even when co-infection 
with HCV is not present. These results suggest the need to investigate potential mechanisms 
of action of HIV and cocaine on liver fibrosis and survival in human studies and for 
developing effective intervention programs in people living with HIV to increase access and 
adherence to treatment, reduce progression of liver fibrosis and prevent early death.
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Figure 1. 
Kaplan-Meier curves comparing the survival of cocaine user assessed by self-report and/or 
urine toxicology or both with that of non-users from the study baseline visit.
Interpretation: Cocaine users had significantly lower survival time than participants who 
did not use cocaine when followed from study baseline for 6 years, P<0.05.
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Figure 2. 
Kaplan-Meier survival curves comparing the survival of cocaine use assessed by either self-
report, urine toxicology or both with that of non-users from the reported years since 
diagnosis.
Interpretation: The Kaplan-Meier curve graphs the survival function over the number of 
years since diagnosis. The survival function describes the probability of surviving past year 
y. For example, the probability of surviving past 20 years after being diagnosed is about 
94.5% for those who did not use cocaine and about 88% for those who use cocaine assessed 
by either self-report or urine toxicology. A drop in the graph (vertical line) represents death 
while the vertical ticks through the horizontal lines represent censored subjects, or subjects 
who did not die within the time frame of the study.
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Figure 3. 
Kaplan-Meier survival curves comparing the survival of participants by severity of liver 
fibrosis estimated by FIB-4 at baseline to the end of study.
Interpretation: From baseline to the end of the study, the probability of surviving is about 
97% for those with no liver fibrosis and approximately 93% for those with mild to 
moderated liver fibrosis and about 80% for those with severe liver fibrosis.
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Figure 4. 
Kaplan-Meier curve comparing survival by severity of liver fibrosis estimated by FIB-4 at 
baseline from the reported years since HIV diagnosis
Interpretation: The Kaplan-Meier curve graphs the survival function over the number of 
years since diagnosis. The survival function describes the probability of surviving past year 
y. For example, the probability of surviving past 20 years after being diagnosed is about 
96% for those with no liver disease (F0–F1), about 91% for those with mild liver disease 
(F2–F3) and roughly 76% for those with severe liver disease (F4–F5)
A drop in the graph (vertical line) represents death while the vertical ticks through the 
horizontal lines represent censored subjects, or subjects who did not die within the time 
frame of the study.
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Table 1
Characteristics of the population.
Characteristics Total (N=487) Cocaine Users (N=156) 2.0% Cocaine non-users (N=331) P-value
Gender (%)
Male 65% 69% 63%
Female 35% 31% 37% 0.101
Age (years) 46.9 ± 7.7 46.4 ± 7.5 47.2 ± 7.8 0.189
Ethnicity (%)
White 6.8% 6.7% 6.9% 0.939
Hispanic 18% 10.1% 21.4% <0.001*
African American 67.8% 73.2% 65.8% 0.023*
Other 7.2% 10.0% 5.9% 0.082
Receiving ART at baseline 81% 75% 84% 0.001*
HIV/HCV co-infected 28.8% 28% 29% 0.619
BMI kg/m2 27.4 ± 5.2 26.9 ± 5.4 27.67 ± 5.1 0.026*
CD4 cells/μL 501.9 ± 346.7 508.8 ± 377.8 499.4 ± 332.3 0.697
HIV viral load log10 copies/mL 2.75 ± 1.3 2.97 ± 1.4 2.64 ± 1.3 <0.001*
FIB-4 ≥ 1.45 63.9% 64.2% 65.4% 0.796
Deaths 5.54% (27/487) 8.33% (13/156) 4.22% (14/337) 0.003*
*Statistically Significant, P<0.05
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Table 2
Mixed model estimates of the effect of cocaine on liver fibrosis over a period of two years.
Four Study Groups β SE* P-value
HIV/HCV using cocaine (N=58) HIV/HCV no cocaine use (N=60) 0.44 0.22 0.049**
HIV mono-infected using cocaine use (N=94) HIV mono-infected no cocaine use (N=76) 0.23 0.11 0.033**
Controlled for age, sex and baseline CD4 cell count and viral load
*SE=Standard Error
**Statistically Significant, P<0.05
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Table 3
Logistic regression of predictors of death in PLWH*.
Predictors Odds Ratio 95% CI** P-value
(N=487) HIV Mono-infected and HIV/HCV Co-infected Persons
Cocaine Use 2.8 1.14, 6.8 0.024†
HIV/HCV co-infection 2.4 1.06, 5.4 0.035†
FIB4 ≥ 1.45 at baseline 3.7 1.23, 11.2 0.019†
(N=347) HIV-Mono-infected Persons Only
Cocaine Use 5.1 1.6, 16.1 0.006†
FIB ≥ 1.45 1.53 1.2, 1.9 <0.001
*All models were controlled for age, gender and HIV viral load at baseline
**95% Confidence Intervals
†
P-value<0.05
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Table 5
Frequency of causes of death according to death certificates.
Cause of Death Frequency*
HIV/AIDS 17
Cardiovascular Disease 13
Respiratory Failure 5
Acute Liver Failure 3
Acute Encephalopathy 2
Acute Renal Failure 2
Pneumonia 2
Septic Shock, Sepsis 2
TB 1
Cocaine and Ethanol Toxicity 1
End Stage Lung Cancer 1
Acetaminophen Overdose 1
Gunshot Wound to the Neck 1
Wasting Syndrome 1
Cerebral Amyloid Angiopathy 1
Total 53
*70.4% (19/27) contained more than one cause of death, 63% (17/27) listed HIV/AIDS one of the causes of death
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